Gout Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Gout Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Gout Therapeutics market is anticipated to grow with a CAGR of 15.5%, over the forecast period (2022 - 2027).

The COVID-19 pandemic has significantly impacted market growth. The onset of the COVID-19 pandemic has caused a nationwide lockdown with the suspension of non-urgent scheduled visits and hospitalizations which resulted in the delayed diagnosis of patients suffering from gout. For instance, according to an article published by the Rheumatology Journal, in March 2022, titled " Gout and the COVID-19 pandemic”, due to concomitant cardiometabolic disorders, people with gout are expected to be at an elevated risk of adverse outcomes following COVID-19 infection. In addition, as per the same source, the COVID-19 epidemic has posed several challenges for people suffering from gout as well as a lack of guidance on the management of gout during the pandemic and scant research evaluating the effects of COVID-19 infection on gout sufferers has impacted the growth of the studied market during the pandemic. Additionally, according to an article published by the Annals of Rheumatic Diseases, in March 2022, titled “Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination”, it has been observed that the COVID-19 vaccine was negatively associated with colchicine prophylaxis and was linked to an elevated risk of gout flares, which primarily appeared in the first month following each dosage. Thus, COVID-19 has a negative impact on the treatment as well as the supply of therapeutics related to gout.

The factors attributed to the growth of the market are the growing adoption of biologics and rising research and development activities on regenerative medicines, the rising prevalence of gout with increasing alcohol consumption, and technological advancements in imaging modalities that improved the understanding of gout.

In addition, the factors that increase the risk of developing gout are obesity, dietary factors, comorbid conditions, and novel associations of gout with other comorbidities, such as erectile dysfunction, atrial fibrillation, obstructive sleep apnea, osteoporosis, and venous thromboembolism have been reported. For instance, according to 2022 statistics published by World Obesity Federation, it has been observed that 31.5% of men and 40.2% of women are living with obesity in Mexico in 2020. Also, according to the Eurostat report in July 2021, more than half (53%) were overweight (36% pre-obese and 17% obese) in Europe in 2020. As per the same source, the highest share of the obese population was found in the people aged 65 to 74 (66%) and the lowest among those aged 18 to 24 (25%). Thus, a high body mass index increases the risk of developing gout by increasing the serum uric acid level in the body and leads to hyperuricemia which decreased the renal secretion of urate. This is expected to increase the demand for effective treatment and therapeutics which is in turn anticipated to propel the market growth.

The rising incidence and prevalence of gout among the population are also contributing to the market growth. For instance, according to an article published by the Annals of Rheumatic Diseases, in June 2021, titled “Has the gout epidemic peaked in the UK? A nationwide cohort study using data from the Clinical Practice Research Datalink, from 1997 to across the COVID-19 pandemic in 2021”, it has been observed that the prevalence rate of gout has been increased from 0.98%in 1997 to 2.33% in 2021. As per the same source, the incidence of gout increased by 0.98/1,000 persons in 2021. Thus, the high burden of gout is expected to increase the demand for drugs treating this condition, which is anticipated to fuel the market growth over the forecast period.

However, the side effects of gout therapeutics drugs and the high indirect costs of gout therapeutics are the factors that are impeding the growth of the market.

Key Market TrendsAntihyperuricemic Agents (Urate-Lowering Drugs) Segment is Expected to Grow with High CAGR Over the Forecast Period in the Gout Therapeutics Market

Gout is the most common form of inflammatory arthritis, characterized by painful and disabling acute attacks. It is caused by hyperuricemia and the deposition of urate crystals, in and around the joints. Antihyperuricemic agents are also called antigout agents. Anti-hyperuricemic medications lower blood uric acid levels either by speeding up urine uric acid excretion or by preventing the production of extra uric acid. Some of the drugs that cause hyperuricemia conditions include salicylates, pyrazinamide, ethambutol, nicotinic acid, cyclosporin, 2-ethylamino-1,3,4-thiadiazole, fructose, and cytotoxic agents.

Some of the most common drugs used in this segment are xanthine oxidase inhibitors (allopurinol and febuxostat), uricosuric medications (benzbromarone, probenecid, and sulfinpyrazone), and uricases (pegloticase and rasburicase).

The antihyperuricemic agent segment is expected to witness significant growth over the forecast period owing to the factors such as the increasing adoption of these drugs for treating gout. For instance, according to an article published by the Annals of Rheumatic Diseases, in June 2021, titled “Has the gout epidemic peaked in the UK? A nationwide cohort study using data from the Clinical Practice Research Datalink, from 1997 to across the COVID-19 pandemic in 2021”, it has been observed that the incidence of gout was 0.98 per 1,000 persons in 2021, as compared to 1.07/1000 persons in 2020. In addition, as per the same source, the prevalence of urate-lowering prescriptions in gout increased from 36.72% in 2019 to 39.53% in 2021. Thus, the increasing prescription of urate-lowering drugs by physicians is likely to increase the demand for antihyperuricemia drugs, thereby fueling market growth.

In addition, the increasing company activities as well as rising clinical trials in developing drugs for the treatment of high uric acid, rising awareness campaigns regarding gout and its effects are also contributing to the market growth. For instance, in August 2021, Eisai and FUJI YAKUHIN CO., LTD. entered into a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in five ASEAN (Association of Southeast Asian Nations) member states Indonesia, Malaysia, Myanmar, the Philippines, and Thailand. Under the agreement, Eisai acquired exclusive development and marketing rights for dotinurad in the said five countries from FUJI YAKUHIN, and FUJI YAKUHIN retained responsibility for manufacturing the formulation of dotinurad and supply to Eisai. Also, in March 2020, Horizon Therapeutics plc launched Down and Out Kidney, a campaign to highlight the damaging effects associated with the accumulation of uric acid and gout in people with chronic kidney disease (CKD).

Therefore, owing to the aforementioned factors, the studied market is expected to grow over the forecast period.

North America Dominates the Market and Expects to do Same in the Forecast Period

North America is expected to account for a major share of the gout therapeutics market over the forecast period, owing to the increasing prevalence of gout, the presence of well-established healthcare infrastructure, and the growing healthcare expenditure. For instance, according to the Organization for Economic Co-operation and Development (OECD), in June 2022, United States healthcare spending in 2021 was 17.8% of the total GDP of the country. Additionally, as per the Centers for Medicare and Medicaid Services, National Health spending is projected to grow at an average annual rate of 5.4% for 2019-2028 and to reach USD 6.2 trillion by 2028. As national health expenditure is projected to grow 1.1% points faster than gross domestic product per year on average over 2019-2028 the health share of the economy is projected to rise by 19.7% in 2028. Thus, the increasing healthcare spending is expected to increase company activities and government initiatives in developing remote patient monitoring, thereby fueling the market growth.

Moreover, the rising product launches are also contributing to the market growth over the forecast period. For instance, in July 2022, the United States Food and Drug Administration approved an expanded label of Horizon’s Krystexxa for improving the treatment outcomes for patients with uncontrolled gout. Also, in January 2021, Dr. Reddy’s Laboratories Ltd. launched Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets in the United States. The tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.

Thus, owing to the aforementioned factors, the studied market is expected to grow over the forecast period.

Competitive Landscape

The gout therapeutics market is fragmented and competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the increasing prevalence of cases across the globe, few other companies are also expected to enter in the market in the coming years. Some of the major players in the market are Lannett Company, Horizon Therapeutics plc, GlaxoSmithKline PLC, Regeneron Pharmaceuticals, and Takeda Pharmaceutical Company Ltd among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.